Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 34Melanoma 13Carcinoma, Hepatocellular 13Neoplasm Metastasis 12Lung Neoplasms 10Squamous Cell Carcinoma of Head and Neck 9Neoplasms 9Esophageal Neoplasms 9Colorectal Neoplasms 6Esophageal Squamous Cell Carcinoma 5Breast Neoplasms 5Recurrence 4Rectal Neoplasms 4Brain Neoplasms 4Uterine Cervical Neoplasms 3Triple Negative Breast Neoplasms 3Sarcoma 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Pancreatic Neoplasms 3Liver Neoplasms 3Head and Neck Neoplasms 3Cholangiocarcinoma 3Carcinoma, Renal Cell 3Stomach Neoplasms 2Small Cell Lung Carcinoma 2Radiation Pneumonitis 2Prostatic Neoplasms 2Pathologic Complete Response 2Parkinson Disease 4, Autosomal Dominant Lewy Body 2Neuroblastoma 2

Interventions

Radiotherapy 1Immunotherapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × HER2-Negative Locally Advanced Breast Cancer × Immunotherapy × Clear all
NCT06908668 2025-04-03

Evaluate the Efficacy and Safety of Adebrelimab Combined With Chemotherapy With or Without Radiotherapy as Neoadjuvant Treatment for HER2-Negative Locally Advanced Breast Cancer

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2 Not yet recruiting
170 enrolled
Breast

HER2-Negative Locally Advanced Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡